Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2

Phase 3UnknownNCT00451984

Aalborg University Hospital80 enrolled

Overview

The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

HIV Infections Hepatitis A Hepatitis B

Interventions

TwinrixBIOLOGICAL

interleukin-2BIOLOGICAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults with stable antiretroviral therapy and negative for hepatitis A or B Exclusion Criteria: * Prior hepatitis A or B

Locations (2)

Department of Infectious Diseases, Aalborg Hospital

Aalborg, Denmark

RECRUITING

Department of Infectious Diseases, Skejby Hospital

Aarhus, Denmark

NOT_YET_RECRUITING

Outcomes

Primary Outcomes

Antibody response to hepatitis A and hepatitis B

Central Contacts

Henrik Nielsen, MD, DMSci

CONTACT

+45-99326525 henrik.nielsen@rn.dk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.